Endo's profits rise as it announces deal with Grunenthal
This article was originally published in Scrip
Executive Summary
Endo Pharmaceuticals has bought the North American rights to Grunenthal's investigational drug axomadol as Endo's fourth-quarter profits rose by 48% to $74.9 million. Net income grew by 15% to $261.7 million for the full year.